Promotions & Discounts

  • Free 2 x 100ul aliquots of Virovek's AAV control vectors for all new customers! More

  • Special offer for all academic and non-profit organizations on Virovek's custom-made AAV vectors. More

  • Timeline & News


    Boston, Massachusetts, June 10-11, 2013 — Virovek was invited to present and showcase its large-scale AAV vector manufacturing process at this inaugural bio-manufacturing and processing summit (ManuBio USA 2013) to an audience composed of senior level delegates from both mid-size and large biopharmaceutical companies.

    Hayward, California, June 3, 2013 — Virovek announced today it has discontinued its baculovirus titration kit, BacEZ Titer Kit, but will still provide technical support to customers who have previously purchased this product.

    Nanjing, China, April 25-27, 2013 — Company CEO, Dr. Haifeng Chen, chaired the Gene Therapy session and presented Virovek’s latest suicide gene therapy technology using toxins to target cancer cells at the BIT’s 4th Annual World DNA and Genome Day (WDD-2013).

    San Francisco, California, January 7-9, 2013 — Virovek presented its newest proprietary technology to manufacture AAV vectors harboring toxins, the first of its kind, at the Biotech Showcase 2013 where private and small- and mid-cap biotechnology companies present their innovations to investors and biopharmaceutical executives.

    San Francisco, California, and Houston, TX, May 16, 2012 — Avalanche Biotechnologies, Inc. and Lonza announced their major global manufacturing collaboration to use Virovek’s proprietary technology to produce AAV vectors for gene therapy studies.

    Hayward, California, June 10, 2011 — Virovek announced that a new book “Methods in Molecular Biology 737 — Viral Vector for Gene Therapy” has been published by Humana Press (Editors: Otto-Wilhelm Merten & Mohamed Al-Rubeai), in which Dr. Haifeng Chen contributed to a chapter describing the use of baculovirus system to manufacture AAV vectors.

    Hayward, California, November 20, 2009 — Virovek announced today that starting on January 1, 2010, Virovek will provide up to 50% discount in fees of AAV vector production services for academic and non-profit organizations in order to facilitate the use of AAV vectors in gene delivery/gene therapy research and cut cost for academic and non-profit organizations.

    Hayward, California, April 10, 2009 — Virovek announced today that it launched a new product, BacEZ Titer Kit, for baculovirus titration. This kit offers customer more reagents for lower cost as compared with other competitors’ similar product. It uses a standard immunological assay to accurately determine the baculovirus titers within 48 hours; whereas other methods, such as plaque and end-point dilution assays, require 4–8 days.

    San Diego, California, January 12, 2009 — Company CEO, Dr. Haifeng Chen, gave a presentation today at the PepTalk 2009 Conference (January 11 – 16, 2009, San Diego, CA) entitled “The Artificial Intron: A New Tool to express Overlapping Genes in Insect Cells Without Using Homologous Sequences.”

    Hayward, California, January 7, 2009 — Virovek announced that it signed a licensing agreement with Massachusetts Institute of Technology (MIT) in which MIT will use Virovek’s AAV production technology for its neuroscience research in the viral core facility newly established by the Picower Institute for Learning and Memory and the McGovern Institute for Brain Research. Rachael Neve, a former faculty member at Harvard Medical School and director of the Molecular Neurogenetics Laboratory at McLean Hospital in Belmont, MA, and one of the world’s foremost experts on gene delivery in the nervous system, will direct the viral core facility.

    Hayward, California, February 6, 2008 — Virovek announced today that its manuscript entitled “Intron splicing-mediated expression of AAV Rep and Cap genes and production of AAV vectors in insect cells” has been accepted for publication in the peer-reviewed journal “Molecular Therapy.” Intron splicing-mediated overlapping gene expression in insect cells has never been reported and this novel technology should greatly promote the use of insect cells for AAV vector production.

    Hayward, California, October 4, 2007 — Virovek launched a free AAV vector production program today to serve the biotechnology and biopharmaceutical research communities. Because of its robustness of the novel AAV production technology, Virovek is able to cut cost on AAV vector production and provide free AAV vector samples to customers.